

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present  
NEWS 3 NOV 26 MARPAT enhanced with FSORT command  
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 5 NOV 26 Two new SET commands increase convenience of STN searching  
NEWS 6 DEC 01 ChemPort single article sales feature unavailable  
NEWS 7 DEC 12 GBFULL now offers single source for full-text coverage of complete UK patent families  
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 9 JAN 06 The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data  
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced  
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art  
NEWS 17 FEB 19 Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01  
NEWS 18 FEB 23 Several formats for image display and print options discontinued in USPATFULL and USPAT2  
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields and 2009 MeSH terms  
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms  
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into STN patent clusters  
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status display data from INPADOCDB  
NEWS 23 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display formats  
NEWS 24 MAR 11 EPFULL backfile enhanced with additional full-text applications and grants  
NEWS 25 MAR 11 ESBIOTBASE reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:23:07 ON 17 MAR 2009

FILE 'REGISTRY' ENTERED AT 10:23:19 ON 17 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2  
DICTIONARY FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2

New CAS Information Use Policies. Enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stndgen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10596745newsearch1.str



```

chain nodes :
7 8 9 10 11 12 14 15 17
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 5-8 8-9 9-10 10-11 11-12 12-14 12-15 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7 9-10 10-11 11-12 12-14 12-15 15-17
exact bonds :
5-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:C,O,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:CLASS 12:CLASS 14:CLASS 15:CLASS 17:Atom


```

L1 STRUCTURE UPLOADED

```

=> d 11
L1 HAS NO ANSWERS
L1 STR

```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 10:23:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      531 TO ITERATE

100.0% PROCESSED      531 ITERATIONS          9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH   **COMPLETE**

PROJECTED ITERATIONS:      9238 TO     12002
PROJECTED ANSWERS:          9 TO       360
```

L2 9 SEA SSS SAM L1

```
=> s l1 sss full
FULL SEARCH INITIATED 10:23:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      10233 TO ITERATE
```

```
100.0% PROCESSED      10233 ITERATIONS          172 ANSWERS
SEARCH TIME: 00.00.02
```

L3 172 SEA SSS FUL L1

=> file caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	185.88	186.10	

```
FILE 'CAPLUS' ENTERED AT 10:24:02 ON 17 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Mar 2009 VOL 150 ISS 12  
FILE LAST UPDATED: 16 Mar 2009 (20090316/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13  
L4 3 L3

=> d ibib abs hitstr 1-3


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:790854 CAPLUS  
DOCUMENT NUMBER: 145:230644  
TITLE: Preparation of pyrimidine derivatives and their use as Tie2 receptor tyrosine kinase inhibitors  
INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited  
SOURCE: PCT Int. Appl., 168pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082373	A1	20060810	WO 2006-GB284	20060127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1863805	A1	20071212	EP 2006-701245	20060127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008528663	T	20080731	JP 2007-553683	20060127
IN 2007DN05604	A	20070817	IN 2007-DN5604	20070719
CN 101137652	A	20080305	CN 2006-80007855	20070911
PRIORITY APPLN. INFO.:			GB 2005-1984 A 20050201	
			GB 2005-2417 A 20050205	
			GB 2005-12614 A 20050621	
			WO 2006-GB284 W 20060127	

OTHER SOURCE(S): CASREACT 145:230644; MARPAT 145:230644  
GI



I




II

AB Substituted pyrimidine derivs. I, wherein R1 is an (un)substituted amine, (un)substituted 3-7 membered heterocyclic ring; R2 and R3 are H, (un)substituted alkyl, (un)substituted alkoxy; A is a 5 or 6 membered heteroaryl ring; R4 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un)substituted amine, alkyl group; B is a cycloalkyl, heterocyclic ring, aryl, heteroaryl, bicyclic ring; R5 is a halo, hydroxyl, amino, alkylamino, cyano, cycloalkyl ring, an (un)substituted 3 to 7 membered heterocyclic ring; m and n are 0-3 are prepared and used as as medicaments and in the production of an anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC50 are 1.5 and 1.9  $\mu\text{M}$  resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.

IT 857265-17-9P, Phenyl[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857266-46-7P, Phenyl 3-[[2-[(3-(dimethylamino)propyl)amino]pyrimidin-5-yl]ethynyl]phenylcarbamate 905439-39-6P 905439-44-3P 905439-48-7P 905439-61-4P 905439-64-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)


RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857266-46-7 CAPLUS

CN Carbamic acid, [3-[[2-[(3-(dimethylamino)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-39-6 CAPLUS

CN Carbamic acid, [5-[(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-44-3 CAPLUS

CN Carbamic acid, [4-methyl-3-[[2-[(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-48-7 CAPLUS

CN Carbamic acid, [6-methyl-5-[[2-[(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-61-4 CAPLUS

CN Carbamic acid, [5-[[2-[(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



RN 905439-64-7 CAPLUS

CN Carbamic acid, [5-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:381241 CAPLUS

DOCUMENT NUMBER: 144:432828

TITLE: Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian L.; Martin, Matthew W.; McGowan, David C.; Dimauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri, Philip R.; Reed, Anthony; Romero, Karina

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 330 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044823	A2	20060427	WO 2005-US37299	20051017
WO 2006044823	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060217380	A1	20060928	US 2005-251490	20051014
AU 2005295414	A1	20060427	AU 2005-295414	20051017
CA 2583907	A1	20060427	CA 2005-2583907	20051017
EP 1802586	A2	20070704	EP 2005-812237	20051017
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-620100P	P 20041018
			US 2005-251490	A 20051014
			WO 2005-US37299	W 20051017
OTHER SOURCE(S):	CASREACT 144:432828; MARPAT 144:432828			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. I, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases, including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5-ethynylpyrimidine (preparation from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC<sub>50</sub> values of less than or equal to 10 μM both for Tie-2 and Lck kinase.

IT 884602-98-6P, N-[4-[2-(2-Aminopyrimidin-5-yl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)urea 884603-00-3P  
 884604-13-1P, N-[3-Methyl-4-[[4-[[2-(methyoxy)phenyl]oxy]-2-[(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of heteroaryl-substituted alkynes as protein

kinase modulators)  
RN 884602-98-6 CAPLUS  
CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 884603-00-3 CAPLUS  
CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)



RN 884604-13-1 CAPLUS  
CN Urea, N-[4-[2-[4-(2-methoxyphenoxy)-2-[[4-(4-methyl-1-piperazinyl)amino]-5-pyrimidinyl]ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


Me

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:588668 CAPLUS  
 DOCUMENT NUMBER: 143:115557  
 TITLE: Preparation of 2-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases  
 INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 178 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060970	A1	20050707	WO 2004-GB5337	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737463	A1	20070103	EP 2004-806139	20041220
EP 1737463	B1	20081203		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1917879	A	20070221	CN 2004-80041901	20041220
JP 2007517007	T	20070628	JP 2006-546306	20041220
AT 415970	T	20081215	AT 2004-806139	20041220
US 20080108608	A1	20080508	US 2006-596745	20060622
IN 2006MN00846	A	20070608	IN 2006-MN846	20060717
PRIORITY APPLN. INFO.:			GB 2003-30000	A 20031224
			GB 2004-16849	A 20040729
			WO 2004-GB5337	W 20041220

OTHER SOURCE(S): CASREACT 143:115557; MARPAT 143:115557  
 GI




AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, 2-amino-5-iodopyrimidine underwent Pd-catalyzed coupling with 3-ethynylaniline in the presence of CuI. The resultant substituted aniline was condensed with a carbamate, which was obtained from Ph chloroformate and 5-amino-3-methylisoxazole, to give urea II. This compound showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC<sub>50</sub> values of 19.871 μM and 0.337 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857265-16-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-17-9P, Phenyl [3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857265-31-7P, N-[3-[[2-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-32-8P, N-[3-[[2-[(3-Aminopropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-46-7P, Phenyl [3-[[2-[(3-dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]carbamate  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857265-16-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857265-31-7 CAPLUS


CN Urea, N-[3-[2-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857265-32-8 CAPLUS  
 CN Urea, N-[3-[2-[2-[(3-aminopropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



RN 857266-46-7 CAPLUS  
 CN Carbamic acid, [3-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl-, phenyl ester (9CI) (CA INDEX NAME)



IT 857264-91-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea 857264-93-8P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)urea 857264-94-9P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)urea 857264-95-0P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluorophenyl)urea 857264-96-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-fluorophenyl)urea 857264-97-2P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-fluorophenyl)urea 857264-98-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857264-99-4P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,5-difluorophenyl)urea 857265-00-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-benzodioxol-5-yl)urea 857265-01-1P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857265-02-2P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-methoxyphenyl)urea 857265-03-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-methoxyphenyl)urea 857265-04-4P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)urea 857265-05-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyanophenyl)urea 857265-06-6P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-chlorophenyl)urea 857265-07-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(cyclopentyl)urea 857265-08-8P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)urea 857265-09-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-

tert-butyl-1,3,4-thiadiazol-2-yl)urea 857265-13-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857265-14-6P, N-[3-[[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857265-15-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857265-18-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-oxopiperidin-3-yl)urea 857265-19-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(methylamino)pyrimidin-5-yl)ethynyl]phenyl]urea 857265-22-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(dimethylamino)pyrimidin-5-yl)ethynyl]phenyl]urea 857265-23-7P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-24-8P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-25-9P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-methoxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-26-0P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(1H-imidazol-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-27-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-methoxypropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-28-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-29-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-30-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-33-9P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-34-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-35-1P, N-[5-[[3-[[5-tert-Butylisoxazol-3-yl)amino]carbonyl]amino]phenyl]ethynyl]pyrimidin-2-yl]glycinamide 857265-36-2P 857265-37-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(1H-imidazol-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-38-4P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyridin-2-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-39-5P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-40-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-41-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyridin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-42-0P , N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-(piperidin-1-yl)propyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-43-1P,  
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-47-5P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-48-6P,  
N-(3-Methylisothiazol-5-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-49-7P,  
N-(3-Fluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-50-0P,  
N-(4-Methoxyphenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-51-1P,  
N-(2-Fluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-52-2P,  
N-(2,5-Difluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-53-3P,  
N-(3,4-Difluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-54-4P,

N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-55-5P,  
N-[3-[(2-(Pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl]urea 857265-56-6P,  
N-(1,3-Benzodioxol-5-yl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-57-7P,  
N-(4-Fluorophenyl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-58-8P,  
N-(3-Chlorophenyl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-59-9P,  
N-(5-Methylisoxazol-3-yl)-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-60-2P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-61-3P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-62-4P,  
N-(5-Methylisoxazol-3-yl)-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-63-5P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-64-6P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-65-7P,  
N-(5-Methylisoxazol-3-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-68-0P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-69-1P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-70-4P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-71-5P,  
N-[5-[(3-[(5-tert-Butylisoxazol-3-yl)amino]carbonyl)amino]phenyl]ethynyl]pyrimidin-2-yl]-2-(2-methoxyethoxy)acetamide 857265-72-6P,  
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-76-0P,  
N-[2-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-78-2P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl]urea 857265-80-6P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl]urea 857265-82-8P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-84-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-85-1P, 2-Phenyl-N-[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857265-86-2P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857265-87-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857265-88-4P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857265-89-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-91-9P,  
N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-92-0P, N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-93-1P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea 857265-94-2P,  
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyrimidin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-96-4P,  
N'-(3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl)-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857265-97-5P,

N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea  
857265-98-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-  
tert-butyl-3-cyclopropyl-1H-pyrazol-5-yl)urea 857265-99-7P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-  
2-yl)urea 857266-00-3P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-  
2-yl)urea 857266-01-4P, N-[3-[(2-Aminopyrimidin-5-  
yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-thiadiazol-2-yl)urea  
857266-02-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-  
tert-butyl-1,3-thiazol-2-yl)urea 857266-03-6P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methylisoxazol-3-  
yl)urea 857266-04-7P, N-[3-[(2-Aminopyrimidin-5-  
yl)ethynyl]phenyl]-N'-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)urea  
857266-05-8P, N'-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-  
methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea  
857266-06-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-  
cyclopropyl-1,3,4-thiadiazol-2-yl)urea 857266-07-0P,  
N-Phenyl-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-09-2P,  
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-10-5P,  
N-[3-[[2-[[3-(Piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-  
N'-(4-(trifluoromethyl)pyridin-2-yl)urea 857266-11-6P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-12-7P,  
N-(3-Methylisoxazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-13-8P,  
N-(2-Methoxyphenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-14-9P,  
N-(3-Fluorophenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-15-0P,  
N-[3-[[2-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-  
butylisoxazol-3-yl)urea 857266-16-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(piperidin-1-  
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-17-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-  
(isopropylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-18-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(2-  
hydroxyethoxy)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-19-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[4-  
(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-20-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-  
(dimethylamino)-1-methylethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-21-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[1-methyl-2-  
(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-22-9P 857266-25-2P 857266-26-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(piperazin-1-  
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-27-4P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[3-(piperazin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-29-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[2-(morpholin-4-  
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-32-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(morpholin-4-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-33-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-34-3P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-36-5P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(morpholin-4-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-37-6P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[2-(morpholin-4-  
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-38-7P,


N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-dimethylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenylurea  
857266-39-8P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-isopropylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenylurea  
857266-40-1P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(3-(piperidin-1-yl)propyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-42-3P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(3-(morpholin-4-yl)propyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-43-4P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-44-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(2-hydroxy-1-oxoethyl)amino]ethyl]amino)pyrimidin-5-yl)ethynylphenylurea  
857266-45-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(2-hydroxyethyl)amino]propyl]amino)pyrimidin-5-yl)ethynylphenylurea  
857266-48-9P, N-[3-[2-[(3-(Dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl]-N'-phenylurea 857266-49-0P,  
N-[3-[2-[(3-(Dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl]-N'-  
(5-methylisoxazol-3-yl)urea 857266-50-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(3-(dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl)-N-methylurea  
857266-51-4P, N'-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857266-53-6P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)-N-methylurea 857266-57-0P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-61-6P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-63-8P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-64-9P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-phenylurea  
857266-65-0P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea 857266-67-2P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-70-7P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-74-1P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenylurea  
857266-78-5P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea  
857266-82-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea 857266-84-3P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-(ethylthio)-1,3,4-thiadiazol-2-yl)urea 857266-86-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-88-7P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-90-1P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-tert-butyl-1H-pyrazol-4-yl)urea 857266-93-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea  
857266-96-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-oxadiazol-2-yl)urea 857266-99-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)urea 857267-02-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-isopropyl-1H-pyrazol-3-yl)urea  
857267-06-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-fluoro-5-(4-methylpiperazin-1-yl)phenyl)urea 857267-09-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]-4-methylphenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857264-91-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857264-93-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857264-94-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857264-95-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)




RN 857264-96-1 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)




RN 857264-97-2 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(4-fluorophenyl)-  
(CA INDEX NAME)




RN 857264-98-3 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(3-methoxyphenyl)-  
(CA INDEX NAME)



RN 857264-99-4 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(2,5-difluorophenyl)-  
(CA INDEX NAME)




RN 857265-00-0 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1,3-benzodioxol-5-yl)-  
(CA INDEX NAME)




RN 857265-01-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857265-02-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)




RN 857265-03-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 857265-04-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 857265-05-5 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)




RN 857265-06-6 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-chlorophenyl)-  
(CA INDEX NAME)




RN 857265-07-7 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-cyclopentyl- (CA INDEX NAME)




RN 857265-08-8 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)- (CA INDEX NAME)




RN 857265-09-9 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857265-13-5 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857265-14-6 CAPLUS  
 CN Acetamide, N-[3-[[[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]phenyl]- (CA INDEX NAME)




RN 857265-15-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)-2-pyridinyl)- (CA INDEX NAME)




RN 857265-18-0 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-oxo-3-piperidinyl)- (CA INDEX NAME)




RN 857265-19-1 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-(methylamino)-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-22-6 CAPLUS  
 CN Urea, N-[3-[2-[2-(dimethylamino)-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857265-23-7 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)



RN 857265-24-8 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)




RN 857265-25-9 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(methoxyethyl)amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)




RN 857265-26-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1H-imidazol-1-yl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-27-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-methoxypropyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-28-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-hydroxyethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-29-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-30-6 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-33-9 CAPLUS  
 CN Urea, N-[3-[2-[2-[(2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-34-0 CAPLUS  
 CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-35-1 CAPLUS  
 CN Acetamide, 2-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 857265-36-2 CAPLUS  
 CN Propanamide, 3-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 857265-37-3 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(1H-imidazol-5-yl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-38-4 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(2-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-39-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-40-8 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

Me


RN 857265-41-9 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(4-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-42-0 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)



RN 857265-43-1 CAPLUS  
CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-47-5 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-48-6 CAPLUS

CN Urea, N-(3-methyl-5-isothiazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-49-7 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-50-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-51-1 CAPLUS

CN Urea, N-(2-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-52-2 CAPLUS

CN Urea, N-(2,5-difluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-53-3 CAPLUS

CN Urea, N-(3,4-difluorophenyl)-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-54-4 CAPLUS


CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-55-5 CAPLUS  
 CN Urea, N-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857265-56-6 CAPLUS  
 CN Urea, N-1,3-benzodioxol-5-yl-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-57-7 CAPLUS  
 CN Urea, N-(4-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-58-8 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-59-9 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-60-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-61-3 CAPLUS  
 CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[3-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-62-4 CAPLUS  
 CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-63-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-64-6 CAPLUS  
 CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-65-7 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-68-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-69-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-70-4 CAPLUS


CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-71-5 CAPLUS

CN Acetamide, N-[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CH<sub>2</sub> — OMe

RN 857265-72-6 CAPLUS


CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-pyridinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-76-0 CAPLUS

CN Urea, N-[2-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyridinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-78-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857265-80-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857265-82-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-84-0 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857265-85-1 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-86-2 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857265-87-3 CAPLUS

CN Benzeneacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-88-4 CAPLUS

CN Benzeneacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-89-5 CAPLUS

CN 5-Isoxazoleacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)




RN 857265-91-9 CAPLUS


CN Benzeneacetamide, N-[4-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857265-92-0 CAPLUS  
 CN 5-Isoxazoleacetamide, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)



RN 857265-93-1 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857265-94-2 CAPLUS  
 CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyrimidinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-96-4 CAPLUS  
 CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857265-97-5 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857265-98-6 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-[3-cyclopropyl-1-(1,1-dimethylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 857265-99-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-00-3 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-01-4 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-02-5 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(4-(1,1-dimethylethyl)-2-thiazolyl)- (CA INDEX NAME)




RN 857266-03-6 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-04-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-05-8 CAPLUS  
CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-06-9 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-07-0 CAPLUS  
CN Urea, N-phenyl-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-09-2 CAPLUS  
CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-10-5 CAPLUS  
CN Urea, N-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857266-11-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-12-7 CAPLUS

CN Urea, N-(3-methyl-5-isoxazolyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-13-8 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-14-9 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-15-0 CAPLUS

CN Urea, N-[3-[2-[2-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-16-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-(1-piperidinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857266-17-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-(1-methylethyl)amino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857266-18-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-hydroxyethoxy)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)


PAGE 1-A



— CH<sub>2</sub>—CH<sub>2</sub>—OH


RN 857266-19-4 CAPLUS

CN Urea, N-[3-[2-[2-[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)




RN 857266-20-7 CAPLUS

CN Urea, N-[3-[2-[2-[2-(dimethylamino)-1-methylethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)




RN 857266-21-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[1-methyl-2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)-(CA INDEX NAME)



RN 857266-22-9 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[1-(2-hydroxyacetyl)-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl)ethynyl]phenyl)-(CA INDEX NAME)



RN 857266-25-2 CAPLUS

CN Urea, N-[3-[2-[2-[[1-[2-(dimethylamino)acetyl]-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


→ Bu-t

RN 857266-26-3 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(1-piperazinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A







RN 857266-27-4 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-29-6 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[3-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-32-1 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-33-2 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-34-3 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-36-5 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-37-6 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-38-7 CAPLUS  
CN Urea, N-[3-[2-[2-[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 857266-39-8 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-[1-methylethyl]amino]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-40-1 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-42-3 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-43-4 CAPLUS


CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-44-5 CAPLUS

CN Acetamide, N-[2-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CH<sub>2</sub> — OH

RN 857266-45-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylpropyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-[2-hydroxyethyl]amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



— CH<sub>2</sub>— OH


RN 857266-48-9 CAPLUS

CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857266-49-0 CAPLUS

CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-50-3 CAPLUS

CN Urea, N'-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-51-4 CAPLUS

CN Urea, N'-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-53-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N-methyl- (CA INDEX NAME)




RN 857266-57-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-61-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-63-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-64-9 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-phenyl- (CA INDEX NAME)

INDEX NAME)




RN 857266-65-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857266-67-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-70-7 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-74-1 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenyl- (CA INDEX NAME)




RN 857266-78-5 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857266-82-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-84-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-86-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-88-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-90-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-(1,1-dimethylethyl)-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 857266-93-4 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-3-(1-methylethyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-96-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 857266-99-0 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 857267-02-8 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1-(1-methylethyl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 857267-06-2 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(3-fluoro-5-(4-methyl-1-piperazinyl)phenyl)- (CA INDEX NAME)



RN 857267-09-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-methylphenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



IT 857266-23-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(pyrrolidin-2-yl)methyl]amino]pyrimidin-5-yl)ethynyl]phenyl]urea  
857266-24-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(1-(tert-

butoxycarbonyl)pyrrolidin-2-yl)methyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-52-5P, Phenyl


[4-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857266-23-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-pyrrolidinylmethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857266-24-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[2-[3-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857266-52-5 CAPLUS

CN Carbamic acid, [4-[2-amino-5-pyrimidinyl]ethynyl]phenyl-, phenyl ester  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	19.92	206.02	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
CA SUBSCRIBER PRICE	ENTRY	SESSION	
	-2.46	-2.46	

FILE 'REGISTRY' ENTERED AT 10:27:44 ON 17 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2  
DICTIONARY FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10596745newsearch2.str




chain nodes :  
1 2 3 4 5 6 8 9 11 12  
chain bonds :  
1-12 2-3 2-12 3-4 4-5 5-6 6-8 6-9 9-11  
exact/norm bonds :  
1-12 2-12 3-4 4-5 5-6 6-8 6-9 9-11  
exact bonds :  
2-3

G1:C,O,N

Match level :  
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:CLASS 6:CLASS 8:CLASS 9:CLASS 11:Atom  
12:Atom  
Element Count :  
Node 12: Limited  
C,C4  
N,N0

L5 STRUCTURE UPLOADED

=> d 15  
L5 HAS NO ANSWERS  
L5 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 15 sss sam
SAMPLE SEARCH INITIATED 10:28:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23221 TO ITERATE
```

```
8.6% PROCESSED      2000 ITERATIONS          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH    **COMPLETE**
PROJECTED ITERATIONS:   455297 TO 473543
PROJECTED ANSWERS:      0 TO      0
```

L6 0 SEA SSS SAM L5

```
=> s c4n2/rf
L7 3631716 C4N2/RF
```

```
=> s 15 sub=l7 sam
SAMPLE SUBSET SEARCH INITIATED 10:28:37 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 1699 TO ITERATE
```

```
100.0% PROCESSED      1699 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01
```

```
PROJECTIONS (WITHIN SPECIFIED SUBSET):      ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 31508 TO 36452
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):     0 TO      0
```

L8 0 SEA SUB=L7 SSS SAM L5

```
=> s 15 sub=l7 full
FULL SUBSET SEARCH INITIATED 10:29:07 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 35713 TO ITERATE
```

```
100.0% PROCESSED      35713 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.02
```

L9 0 SEA SUB=L7 SSS FUL L5

```
=> s 15 sss full
FULL SEARCH INITIATED 10:29:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 463761 TO ITERATE
```

```
100.0% PROCESSED      463761 ITERATIONS          0 ANSWERS
```

SEARCH TIME: 00.00.16

L10 0 SEA SSS FUL L5

=>

Uploading C:\Program Files\STNEXP\Queries\10596745newsearch3.str



chain nodes :

1 2 3 4 5 6 8 9 11 12

chain bonds :

1-12 2-3 2-12 3-4 4-5 5-6 6-8 6-9 9-11

exact/norm bonds :

1-12 2-12 3-4 4-5 5-6 6-8 6-9 9-11

exact bonds :

2-3

G1:C,O,N

Match level :

1:CLASS 2:CLASS 3:CLASS 4:Atom 5:CLASS 6:CLASS 8:CLASS 9:CLASS 11:Atom

12:Atom

Element Count :

Node 12: Limited

C,C4


N,N2

L11 STRUCTURE UPLOADED

=> d 111

L11 HAS NO ANSWERS

L11 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l11 sss sam
SAMPLE SEARCH INITIATED 10:31:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23221 TO ITERATE
```

```
8.6% PROCESSED      2000 ITERATIONS           1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE   **COMPLETE**
BATCH     **COMPLETE**
PROJECTED ITERATIONS:    455297 TO    473543
PROJECTED ANSWERS:        28 TO      436
```

L12                1 SEA SSS SAM L11

```
=> s l11 sss full
FULL SEARCH INITIATED 10:31:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 463761 TO ITERATE
```

```
100.0% PROCESSED    463761 ITERATIONS       225 ANSWERS
SEARCH TIME: 00.00.13
```

L13                225 SEA SSS FUL L11

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	564.91	770.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.46

```
FILE 'CAPLUS' ENTERED AT 10:31:58 ON 17 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Mar 2009 VOL 150 ISS 12  
FILE LAST UPDATED: 16 Mar 2009 (20090316/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13  
L14                    5 L13



=> d ibib abs hitstr 1-5

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:792996 CAPLUS  
DOCUMENT NUMBER: 145:211064  
TITLE: Preparation of pyrimidine derivatives and their use as Tie2 receptor tyrosine kinase inhibitors  
INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited  
SOURCE: PCT Int. Appl., 116pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082404	A1	20060810	WO 2006-GB352	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1848715	A1	20071031	EP 2006-709603	20060202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008535780	T	20080904	JP 2007-553692	20060202
IN 2007DN05606	A	20070817	IN 2007-DN5606	20070719
US 20080153838	A1	20080626	US 2007-815523	20070803
CN 101155807	A	20080402	CN 2006-80011279	20071008
PRIORITY APPLN. INFO.:			GB 2005-2418                    A 20050205	
			WO 2006-GB352                    W 20060202	

OTHER SOURCE(S):  
GI

CASREACT 145:211064; MARPAT 145:211064



AB Substituted heterocyclic and heteroaryl derivs. I, wherein A is an aryl or 5 or 6 membered heteroaryl ring; B is a cycloalkyl 3 to 7 membered heterocycle, aryl, 5 or 6 membered heteroaryl or an 8-10 membered bicyclic; D is a 5 or 6 membered nitrogen containing heteroaryl optionally substituted by oxygen, nitrogen or sulfur atoms; L is attached meta or para on the ethynyl group of A by a (un)substituted amide, (un)substituted carbamate, sulfonate, sulfonamide, a direct bond, or bound to an O or an (un)substituted N; R1 is H, hydroxy, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, (un)substituted heteroaryl or heterocyclic ring, (un)substituted amine; R2 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un)substituted amine, alkyl group; R3 is halo, cyano, oxo, cycloalkyl, 3 to 7 membered heterocycle; m, n, p are 0-3 are prepared and used as as medicaments and in the production of

an

anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC50 are 2.6 and 0.031  $\mu$ M resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.


IT 905286-90-0P 905286-92-2P 905286-95-5P  
905286-96-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)


RN 905286-90-0 CAPLUS

CN Urea, N-[3-[2-(5-amino-2-pyrazinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 905286-92-2 CAPLUS

CN Urea, N-[3-[2-(6-amino-3-pyridazinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)



RN 905286-95-5 CAPLUS


CN Acetamide, N-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrazinyl-(CA INDEX NAME)



RN 905286-96-6 CAPLUS

CN Acetamide, N-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrazinyl]-2-(2-methoxyethoxy)-(CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— CH<sub>2</sub> — OMe

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:790854 CAPLUS

DOCUMENT NUMBER: 145:230644


TITLE: Preparation of pyrimidine derivatives and their use as Tie2 receptor tyrosine kinase inhibitors

INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; Mccoull, William


PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited  
 SOURCE: PCT Int. Appl., 168pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082373	A1	20060810	WO 2006-GB284	20060127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1863805	A1	20071212	EP 2006-701245	20060127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008528663	T	20080731	JP 2007-553683	20060127
IN 2007DN05604	A	20070817	IN 2007-DN5604	20070719
CN 101137652	A	20080305	CN 2006-80007855	20070911
PRIORITY APPLN. INFO.:			GB 2005-1984	A 20050201
			GB 2005-2417	A 20050205
			GB 2005-12614	A 20050621
			WO 2006-GB284	W 20060127

OTHER SOURCE(S): CASREACT 145:230644; MARPAT 145:230644  
 GI



I




II


AB Substituted pyrimidine derivs. I, wherein R1 is an (un)substituted amine, (un)substituted 3-7 membered heterocyclic ring; R2 and R3 are H, (un)substituted alkyl, (un)substituted alkoxy; A is a 5 or 6 membered heteroaryl ring; R4 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un)substituted amine, alkyl group; B is a cycloalkyl, heterocyclic ring,

aryl, heteroaryl, bicyclic ring; R5 is a halo, hydroxyl, amino, alkylamino, cyano, cycloalkyl ring, an (un)substituted 3 to 7 membered heterocyclic ring; m and n are 0-3 are prepared and used as as medicaments and in the production of an anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC<sub>50</sub> are 1.5 and 1.9 μM resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.


- IT 857265-17-9P, Phenyl[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857266-46-7P, Phenyl 3-[[2-[(3-(dimethylamino)propyl)amino]pyrimidin-5-yl]ethynyl]phenylcarbamate 857287-13-9P, Phenyl[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 905439-39-6P 905439-44-3P 905439-48-7P 905439-61-4P 905439-64-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)
- RN 857265-17-9 CAPLUS  
 CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




- RN 857266-46-7 CAPLUS  
 CN Carbamic acid, [3-[[2-[(3-(dimethylamino)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



- RN 857287-13-9 CAPLUS  
 CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




- RN 905439-39-6 CAPLUS  
 CN Carbamic acid, [5-[(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-44-3 CAPLUS

CN Carbamic acid, [4-methyl-3-[[2-[(2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-48-7 CAPLUS

CN Carbamic acid, [6-methyl-5-[[2-[(2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-61-4 CAPLUS

CN Carbamic acid, [5-[[2-[(2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



RN 905439-64-7 CAPLUS

CN Carbamic acid, [5-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:381241 CAPLUS

DOCUMENT NUMBER: 144:432828

TITLE: Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian L.; Martin, Matthew W.; McGowan, David C.; Dimauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri, Philip R.; Reed, Anthony; Romero, Karina

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 330 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044823	A2	20060427	WO 2005-US37299	20051017
WO 2006044823	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060217380	A1	20060928	US 2005-251490	20051014
AU 2005295414	A1	20060427	AU 2005-295414	20051017
CA 2583907	A1	20060427	CA 2005-2583907	20051017
EP 1802586	A2	20070704	EP 2005-812237	20051017
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-620100P	P 20041018
			US 2005-251490	A 20051014
			WO 2005-US37299	W 20051017
OTHER SOURCE(S): GI	CASREACT 144:432828; MARPAT 144:432828			

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. I, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases, including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5-ethynylpyrimidine (preparation from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC50 values of less than or equal to 10  $\mu$ M both for Tie-2 and Lck kinase.

IT 884602-98-6P, N-[4-[2-(2-Aminopyrimidin-5-yl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)urea 884603-00-3P  
 884604-13-1P, N-[3-Methyl-4-[[4-[[2-(methyoxy)phenyl]oxy]-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl-substituted alkynes as protein kinase modulators)


RN 884602-98-6 CAPLUS

CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 884603-00-3 CAPLUS


CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)



RN 884604-13-1 CAPLUS

CN Urea, N-[4-[2-[4-(2-methoxyphenoxy)-2-[(4-(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

   Me

REFERENCE COUNT:



10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:588668 CAPLUS  
 DOCUMENT NUMBER: 143:115557  
 TITLE: Preparation of 2-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases  
 INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 178 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060970	A1	20050707	WO 2004-GB5337	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737463	A1	20070103	EP 2004-806139	20041220
EP 1737463	B1	20081203		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1917879	A	20070221	CN 2004-80041901	20041220
JP 2007517007	T	20070628	JP 2006-546306	20041220
AT 415970	T	20081215	AT 2004-806139	20041220
US 20080108608	A1	20080508	US 2006-596745	20060622
IN 2006MN00846	A	20070608	IN 2006-MN846	20060717
PRIORITY APPLN. INFO.:			GB 2003-30000	A 20031224
			GB 2004-16849	A 20040729
			WO 2004-GB5337	W 20041220

OTHER SOURCE(S): CASREACT 143:115557; MARPAT 143:115557  
 GI




AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, 2-amino-5-iodopyrimidine underwent Pd-catalyzed coupling with 3-ethynylaniline in the presence of CuI. The resultant substituted aniline was condensed with a carbamate, which was obtained from Ph chloroformate and 5-amino-3-methylisoxazole, to give urea II. This compound showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC<sub>50</sub> values of 19.871 μM and 0.337 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857265-16-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-17-9P, Phenyl  
 [3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857265-31-7P  
 , N-[3-[[2-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-32-8P,  
 N-[3-[[2-[(3-Aminopropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-46-7P, Phenyl  
 [3-[[2-[(3-dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]carbamate  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857265-16-8 CAPPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-17-9 CAPPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857265-31-7 CAPPLUS


CN Urea, N-[3-[2-[2-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857265-32-8 CAPLUS  
 CN Urea, N-[3-[2-[2-[(3-aminopropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



RN 857266-46-7 CAPLUS  
 CN Carbamic acid, [3-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl-, phenyl ester (9CI) (CA INDEX NAME)



IT 857264-91-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea 857264-93-8P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)urea 857264-94-9P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)urea 857264-95-0P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluorophenyl)urea 857264-96-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-fluorophenyl)urea 857264-97-2P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-fluorophenyl)urea 857264-98-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857264-99-4P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,5-difluorophenyl)urea 857265-00-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-benzodioxol-5-yl)urea 857265-01-1P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857265-02-2P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-methoxyphenyl)urea 857265-03-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-methoxyphenyl)urea 857265-04-4P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)urea 857265-05-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyanophenyl)urea 857265-06-6P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-chlorophenyl)urea 857265-07-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(cyclopentyl)urea 857265-08-8P,  
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)urea 857265-09-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-

tert-butyl-1,3,4-thiadiazol-2-yl)urea 857265-13-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857265-14-6P, N-[3-[[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857265-15-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857265-18-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-oxopiperidin-3-yl)urea 857265-19-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-22-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(dimethylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-23-7P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-24-8P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-25-9P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-methoxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-26-0P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(1H-imidazol-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-27-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-methoxypropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-28-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-29-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-30-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-33-9P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-34-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-35-1P, N-[5-[[3-[[5-tert-Butylisoxazol-3-yl)amino]carbonyl]amino]phenyl]ethynyl]pyrimidin-2-yl]glycinamide 857265-36-2P 857265-37-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(1H-imidazol-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-38-4P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyridin-2-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-39-5P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-40-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-41-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyridin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-42-0P , N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-(piperidin-1-yl)propyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-43-1P,  
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-47-5P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-48-6P,  
N-(3-Methylisothiazol-5-yl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-49-7P,  
N-(3-Fluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-50-0P,  
N-(4-Methoxyphenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-51-1P,  
N-(2-Fluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-52-2P,  
N-(2,5-Difluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-53-3P,  
N-(3,4-Difluorophenyl)-N'-[3-[[2-[(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-54-4P,

N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-55-5P,  
N-[3-[(2-(Pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl]urea 857265-56-6P,  
N-(1,3-Benzodioxol-5-yl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-57-7P,  
N-(4-Fluorophenyl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-58-8P,  
N-(3-Chlorophenyl)-N'-(3-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-59-9P,  
N-(5-Methylisoxazol-3-yl)-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-60-2P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-61-3P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-(morpholin-4-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-62-4P,  
N-(5-Methylisoxazol-3-yl)-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-63-5P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-64-6P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[(2-[(3-(morpholin-4-yl)propyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-65-7P,  
N-(5-Methylisoxazol-3-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-68-0P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-69-1P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-70-4P,  
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(4-[(2-(pyrrolidin-1-yl)ethyl]amino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-71-5P,  
N-[5-[(3-[(5-tert-Butylisoxazol-3-yl)amino]carbonyl)amino]phenyl]ethynyl]pyrimidin-2-yl]-2-(2-methoxyethoxy)acetamide 857265-72-6P,  
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-76-0P,  
N-[2-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-78-2P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl]urea 857265-80-6P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl]urea 857265-82-8P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-84-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-85-1P, 2-Phenyl-N-[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857265-86-2P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857265-87-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857265-88-4P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857265-89-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-91-9P,  
N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-92-0P, N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-93-1P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea 857265-94-2P,  
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyrimidin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-96-4P,  
N'-(3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl)-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857265-97-5P,

N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea  
857265-98-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-  
tert-butyl-3-cyclopropyl-1H-pyrazol-5-yl)urea 857265-99-7P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-  
2-yl)urea 857266-00-3P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-  
2-yl)urea 857266-01-4P, N-[3-[(2-Aminopyrimidin-5-  
yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-thiadiazol-2-yl)urea  
857266-02-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-  
tert-butyl-1,3-thiazol-2-yl)urea 857266-03-6P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methylisoxazol-3-  
yl)urea 857266-04-7P, N-[3-[(2-Aminopyrimidin-5-  
yl)ethynyl]phenyl]-N'-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)urea  
857266-05-8P, N'-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-  
methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea  
857266-06-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-  
cyclopropyl-1,3,4-thiadiazol-2-yl)urea 857266-07-0P,  
N-Phenyl-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-09-2P,  
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-10-5P,  
N-[3-[[2-[[3-(Piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-  
N'-(4-(trifluoromethyl)pyridin-2-yl)urea 857266-11-6P,  
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-12-7P,  
N-(3-Methylisoxazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-13-8P,  
N-(2-Methoxyphenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-14-9P,  
N-(3-Fluorophenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-  
yl]ethynyl]phenyl]urea 857266-15-0P,  
N-[3-[[2-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-  
butylisoxazol-3-yl)urea 857266-16-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(piperidin-1-  
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-17-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-  
(isopropylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-18-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-  
hydroxyethoxy)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-19-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(4-  
(dimethylamino)butyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-20-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-  
(dimethylamino)-1-methylethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-21-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(1-methyl-2-  
(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
857266-22-9P 857266-25-2P 857266-26-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-(piperazin-1-  
yl)ethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-27-4P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[3-(piperazin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-29-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[(2-(morpholin-4-  
yl)ethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-32-1P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(morpholin-4-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-33-2P,  
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-34-3P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-36-5P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(morpholin-4-  
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-37-6P,  
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[(2-(morpholin-4-  
yl)ethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-38-7P,


N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-dimethylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenylurea  
857266-39-8P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-isopropylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenylurea  
857266-40-1P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(3-(piperidin-1-yl)propyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-42-3P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(3-(morpholin-4-yl)propyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-43-4P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-5-yl)ethynylphenylurea  
857266-44-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(2-hydroxy-1-oxoethyl)amino]ethyl]amino)pyrimidin-5-yl)ethynylphenylurea  
857266-45-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(2-hydroxyethyl)amino]propyl]amino)pyrimidin-5-yl)ethynylphenylurea  
857266-48-9P, N-[3-[2-[(3-(Dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl]-N'-phenylurea 857266-49-0P,  
N-[3-[2-[(3-(Dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl]-N'-  
(5-methylisoxazol-3-yl)urea 857266-50-3P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[(3-(dimethylamino)propyl)amino]pyrimidin-5-yl]ethynylphenyl)-N-methylurea  
857266-51-4P, N'-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857266-53-6P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)-N-methylurea 857266-57-0P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-61-6P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-63-8P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-64-9P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-phenylurea  
857266-65-0P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea 857266-67-2P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-70-7P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-74-1P,  
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenylurea  
857266-78-5P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)urea  
857266-82-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea 857266-84-3P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-(ethylthio)-1,3,4-thiadiazol-2-yl)urea 857266-86-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-88-7P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-90-1P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-tert-butyl-1H-pyrazol-4-yl)urea 857266-93-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea  
857266-96-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-oxadiazol-2-yl)urea 857266-99-0P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)urea 857267-02-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-isopropyl-1H-pyrazol-3-yl)urea  
857267-06-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-fluoro-5-(4-methylpiperazin-1-yl)phenyl)urea 857267-09-5P,  
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]-4-methylphenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857264-91-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857264-93-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857264-94-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857264-95-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)




RN 857264-96-1 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)




RN 857264-97-2 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(4-fluorophenyl)-  
(CA INDEX NAME)




RN 857264-98-3 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(3-methoxyphenyl)-  
(CA INDEX NAME)



RN 857264-99-4 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(2,5-difluorophenyl)-  
(CA INDEX NAME)




RN 857265-00-0 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1,3-benzodioxol-5-yl)-  
(CA INDEX NAME)




RN 857265-01-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857265-02-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)




RN 857265-03-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 857265-04-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 857265-05-5 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)




RN 857265-06-6 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-chlorophenyl)-  
(CA INDEX NAME)




RN 857265-07-7 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-cyclopentyl- (CA INDEX NAME)




RN 857265-08-8 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)- (CA INDEX NAME)




RN 857265-09-9 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857265-13-5 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857265-14-6 CAPLUS  
 CN Acetamide, N-[3-[[[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]phenyl]- (CA INDEX NAME)




RN 857265-15-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)-2-pyridinyl)- (CA INDEX NAME)




RN 857265-18-0 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-oxo-3-piperidinyl)- (CA INDEX NAME)




RN 857265-19-1 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-22-6 CAPLUS  
 CN Urea, N-[3-[2-[2-(dimethylamino)-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857265-23-7 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)



RN 857265-24-8 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)




RN 857265-25-9 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(methoxyethyl)amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)




RN 857265-26-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1H-imidazol-1-yl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-27-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-methoxypropyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-28-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-hydroxyethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-29-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-30-6 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-33-9 CAPLUS  
 CN Urea, N-[3-[2-[2-[(2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-34-0 CAPLUS  
 CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-35-1 CAPLUS  
 CN Acetamide, 2-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 857265-36-2 CAPLUS  
 CN Propanamide, 3-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 857265-37-3 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(1H-imidazol-5-yl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-38-4 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(2-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-39-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-40-8 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

Me


RN 857265-41-9 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(4-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-42-0 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)



RN 857265-43-1 CAPLUS  
CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-47-5 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-48-6 CAPLUS

CN Urea, N-(3-methyl-5-isothiazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-49-7 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-50-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-51-1 CAPLUS

CN Urea, N-(2-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-52-2 CAPLUS

CN Urea, N-(2,5-difluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-53-3 CAPLUS

CN Urea, N-(3,4-difluorophenyl)-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-54-4 CAPLUS


CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-55-5 CAPLUS  
 CN Urea, N-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857265-56-6 CAPLUS  
 CN Urea, N-1,3-benzodioxol-5-yl-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-57-7 CAPLUS  
 CN Urea, N-(4-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-58-8 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-59-9 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-60-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-61-3 CAPLUS  
 CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[3-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-62-4 CAPLUS  
 CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-63-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-64-6 CAPLUS  
 CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-65-7 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-68-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-69-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-70-4 CAPLUS


CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-71-5 CAPLUS

CN Acetamide, N-[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CH<sub>2</sub> — OMe

RN 857265-72-6 CAPLUS


CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-pyridinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-76-0 CAPLUS

CN Urea, N-[2-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyridinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-78-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857265-80-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857265-82-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-84-0 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857265-85-1 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-86-2 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857265-87-3 CAPLUS

CN Benzeneacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-88-4 CAPLUS

CN Benzeneacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-89-5 CAPLUS

CN 5-Isoxazoleacetamide, N-[3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)




RN 857265-91-9 CAPLUS


CN Benzeneacetamide, N-[4-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857265-92-0 CAPLUS  
 CN 5-Isoxazoleacetamide, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)



RN 857265-93-1 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857265-94-2 CAPLUS  
 CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyrimidinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-96-4 CAPLUS  
 CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857265-97-5 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857265-98-6 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-[3-cyclopropyl-1-(1,1-dimethylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 857265-99-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-00-3 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-01-4 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-02-5 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(4-(1,1-dimethylethyl)-2-thiazolyl)- (CA INDEX NAME)




RN 857266-03-6 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-04-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-05-8 CAPLUS  
CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-06-9 CAPLUS  
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-07-0 CAPLUS  
CN Urea, N-phenyl-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-09-2 CAPLUS  
CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-10-5 CAPLUS  
CN Urea, N-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857266-11-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-12-7 CAPLUS

CN Urea, N-(3-methyl-5-isoxazolyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-13-8 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-14-9 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-15-0 CAPLUS

CN Urea, N-[3-[2-[2-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-16-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-(1-piperidinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857266-17-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-(1-methylethyl)amino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857266-18-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-hydroxyethoxy)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)


PAGE 1-A



— CH<sub>2</sub>—CH<sub>2</sub>—OH


RN 857266-19-4 CAPLUS

CN Urea, N-[3-[2-[2-[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)




RN 857266-20-7 CAPLUS

CN Urea, N-[3-[2-[2-[2-(dimethylamino)-1-methylethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)




RN 857266-21-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[1-methyl-2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)-(CA INDEX NAME)



RN 857266-22-9 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[1-(2-hydroxyacetyl)-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl)ethynyl]phenyl)-(CA INDEX NAME)



RN 857266-25-2 CAPLUS

CN Urea, N-[3-[2-[2-[[1-[2-(dimethylamino)acetyl]-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


→ Bu-t

RN 857266-26-3 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(1-piperazinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A







RN 857266-27-4 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-29-6 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[2-[4-morpholinyl]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-32-1 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-33-2 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-34-3 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-36-5 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-37-6 CAPLUS  
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-38-7 CAPLUS  
CN Urea, N-[3-[2-[2-[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 857266-39-8 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(1-methylethyl)amino]ethyl]amino]-5-pyrimidinyl]ethynylphenyl]- (CA INDEX NAME)




RN 857266-40-1 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-42-3 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-43-4 CAPLUS


CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-44-5 CAPLUS

CN Acetamide, N-[2-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CH<sub>2</sub> — OH

RN 857266-45-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylpropyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-[2-hydroxyethyl]amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



— CH<sub>2</sub>— OH


RN 857266-48-9 CAPLUS

CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857266-49-0 CAPLUS

CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-50-3 CAPLUS

CN Urea, N'-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-51-4 CAPLUS

CN Urea, N'-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-53-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N-methyl- (CA INDEX NAME)




RN 857266-57-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-61-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-63-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-64-9 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-phenyl- (CA INDEX NAME)

INDEX NAME)




RN 857266-65-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857266-67-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-70-7 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-74-1 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenyl- (CA INDEX NAME)




RN 857266-78-5 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)




RN 857266-82-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-84-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-86-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-88-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-90-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-(1,1-dimethylethyl)-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 857266-93-4 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-3-(1-methylethyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-96-7 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 857266-99-0 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 857267-02-8 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(1-(1-methylethyl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 857267-06-2 CAPLUS  
 CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-N'-(3-fluoro-5-(4-methyl-1-piperazinyl)phenyl)- (CA INDEX NAME)



RN 857267-09-5 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-methylphenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



IT 857266-23-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(2-[(pyrrolidin-2-yl)methyl]amino)pyrimidin-5-yl]ethynyl]phenyl)urea  
 857266-24-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(2-[(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl]amino)pyrimidin-5-yl]ethynyl]phenyl)urea 857266-52-5P, Phenyl[4-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857266-23-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-pyrrolidinylmethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857266-24-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[2-[3-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857266-52-5 CAPLUS

CN Carbamic acid, [4-[2-amino-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588667 CAPLUS

DOCUMENT NUMBER: 143:115556

TITLE: Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases

INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060969	A1	20050707	WO 2004-GB5332	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737462	A1	20070103	EP 2004-806134	20041220
EP 1737462	B1	20080730		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1917880	A	20070221	CN 2004-80041936	20041220
JP 2007517006	T	20070628	JP 2006-546305	20041220

AT 402705	T 20080815	AT 2004-806134	20041220
ES 2309591	T3 20081216	ES 2004-806134	20041220
US 20080027076	A1 20080131	US 2006-596740	20060622
IN 2006MN00847	A 20070420	IN 2006-MN847	20060717
HK 1102045	A1 20081031	HK 2007-106766	20070625
PRIORITY APPLN. INFO.:		GB 2003-30001	A 20031224
		GB 2004-16850	A 20040729
		WO 2004-GB5332	W 20041220

OTHER SOURCE(S): CASREACT 143:115556; MARPAT 143:115556  
GI




AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, urea II was synthesized in 21% yield by condensation of the corresponding aniline with Ph thiadiazolylcarbamate in the presence of Et3N in THF under microwave irradiation. This urea showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 0.879 μM and 5.557 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.


IT 857287-13-9P, Phenyl [3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-53-7P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857287-13-9 CAPLUS

CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-53-7 CAPLUS  
 CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[4-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




IT 857287-02-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857287-04-8P,  
 2-Phenyl-N-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]acetamide  
 857287-05-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)urea 857287-06-0P,  
 N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)urea 857287-07-1P,  
 N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857287-08-2P,  
 N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)urea 857287-09-3P,  
 N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea 857287-10-6P,  
 N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea  
 857287-11-7P, Phenyl [4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-14-0P,  
 N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-15-1P,  
 N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-16-2P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-17-3P,  
 N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-18-4P,  
 N-[3-[[[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide  
 857287-19-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-20-8P,  
 N-[3-[[[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide  
 857287-21-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-22-0P,  
 N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-23-1P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-24-2P,  
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-25-3P,

N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 857287-26-4P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(morpholin-4-yl)phenyl]urea 857287-27-5P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-methylpiperidin-4-yl)urea 857287-28-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-propylpiperidin-4-yl)urea 857287-29-7P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857287-30-0P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857287-31-1P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857287-32-2P,  
N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857287-35-5P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[(4-(methylamino)pyrimidin-5-yl)ethynyl]phenyl]urea 857287-36-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-37-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(5-tert-butylisoxazol-3-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-39-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-40-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2-hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-41-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-42-4P,  
N-[3-[[4-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-43-5P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-44-6P,  
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2,4-dimethoxybenzyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-45-7P, N-[3-[[4-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-46-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-47-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[4-(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-48-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[N-[(2-(dimethylamino)ethyl)methylamino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-49-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(piperidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-50-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-51-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-52-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-57-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)urea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857287-02-6 CAPLUS  
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857287-04-8 CAPLUS  
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-05-9 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 857287-06-0 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-trifluoromethylphenyl)- (CA INDEX NAME)




RN 857287-07-1 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-trifluoromethylphenyl)- (CA INDEX NAME)




RN 857287-08-2 CAPLUS  
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857287-09-3 CAPLUS  
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857287-10-6 CAPLUS  
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)



RN 857287-11-7 CAPLUS  
CN Carbamic acid, [4-[ (4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-14-0 CAPLUS  
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857287-15-1 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)




RN 857287-16-2 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-17-3 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-18-4 CAPLUS

CN Acetamide, N-[3-[[[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 857287-19-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)




RN 857287-20-8 CAPLUS

CN Acetamide, N-[3-[[[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 857287-21-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-22-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-23-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857287-24-2 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-25-3 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)




RN 857287-26-4 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-(4-morpholinyl)phenyl)- (CA INDEX NAME)




RN 857287-27-5 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 857287-28-6 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 857287-29-7 CAPLUS  
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857287-30-0 CAPLUS  
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 857287-31-1 CAPLUS  
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-32-2 CAPLUS  
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857287-35-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-36-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[3-(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-37-7 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-38-8 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857287-39-9 CAPLUS

CN Urea, N-[3-[2-[4-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-40-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(2-hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-41-3 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(2-(4-morpholinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-42-4 CAPLUS  
CN Urea, N-[3-[2-[4-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-43-5 CAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(3-(1-pyrrolidinyl)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-44-6 CAPLUS  
CN Urea, N-[3-[2-[4-[(2,4-dimethoxyphenyl)methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-45-7 CAPLUS  
CN Urea, N-[3-[2-[4-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-46-8 CAPLUS  
 CN Urea, N-[3-[2-[4-[(2-(dimethylamino)ethyl)amino]ethyl]amino]-5-pyrimidinyl]ethynylphenyl-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-47-9 CAPLUS  
 CN Urea, N-[3-[2-[4-[(4-(dimethylamino)butyl)amino]ethyl]amino]-5-pyrimidinyl]ethynylphenyl-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-48-0 CAPLUS  
 CN Urea, N-[3-[2-[4-[(2-(dimethylamino)ethyl)methylamino]ethyl]amino]-5-pyrimidinyl]ethynylphenyl-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-49-1 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(2-(1-piperidinyl)ethyl)amino]-5-pyrimidinyl]ethynylphenyl)- (CA INDEX NAME)




RN 857287-50-4 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(3-(4-morpholinyl)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-51-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(3-(1-piperidinyl)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857287-52-6 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(3-(4-methyl-1-piperazinyl)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857287-57-1 CAPLUS  
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	37.70	808.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.10	-6.56

STN INTERNATIONAL LOGOFF AT 10:43:27 ON 17 MAR 2009